Piper Sandler Reaffirms Overweight Rating for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Piper Sandler restated their overweight rating on shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) in a report published on Thursday morning, Benzinga reports. They currently have a $71.00 target price on the stock.

AMPH has been the topic of a number of other reports. Needham & Company LLC reissued a hold rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, May 22nd. JPMorgan Chase & Co. began coverage on Amphastar Pharmaceuticals in a report on Tuesday, March 5th. They set an overweight rating and a $60.00 target price on the stock. Finally, StockNews.com raised Amphastar Pharmaceuticals from a hold rating to a buy rating in a report on Monday, May 13th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of Moderate Buy and an average price target of $66.00.

Amphastar Pharmaceuticals Stock Down 0.9 %

NASDAQ:AMPH opened at $40.00 on Thursday. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of 13.84, a price-to-earnings-growth ratio of 0.83 and a beta of 0.82. Amphastar Pharmaceuticals has a twelve month low of $38.43 and a twelve month high of $67.66. The stock’s 50 day moving average price is $41.61 and its two-hundred day moving average price is $47.85. The company has a quick ratio of 1.72, a current ratio of 2.18 and a debt-to-equity ratio of 0.88.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Wednesday, May 8th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.20. The business had revenue of $171.84 million for the quarter, compared to analyst estimates of $171.13 million. Amphastar Pharmaceuticals had a return on equity of 29.17% and a net margin of 22.88%. Equities research analysts expect that Amphastar Pharmaceuticals will post 3.6 earnings per share for the current fiscal year.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 3,596 shares of the company’s stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $40.93, for a total value of $147,184.28. Following the transaction, the chief financial officer now directly owns 94,103 shares of the company’s stock, valued at approximately $3,851,635.79. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CFO William J. Peters sold 3,596 shares of the company’s stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $40.93, for a total transaction of $147,184.28. Following the completion of the sale, the chief financial officer now directly owns 94,103 shares in the company, valued at approximately $3,851,635.79. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Floyd F. Petersen sold 3,000 shares of the company’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $41.40, for a total value of $124,200.00. Following the sale, the director now owns 78,409 shares of the company’s stock, valued at $3,246,132.60. The disclosure for this sale can be found here. Insiders have sold a total of 8,096 shares of company stock valued at $335,259 in the last ninety days. 27.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Amphastar Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. lifted its position in shares of Amphastar Pharmaceuticals by 7.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 379,480 shares of the company’s stock valued at $23,471,000 after acquiring an additional 27,102 shares during the period. Epoch Investment Partners Inc. lifted its position in shares of Amphastar Pharmaceuticals by 348.7% during the 4th quarter. Epoch Investment Partners Inc. now owns 592,530 shares of the company’s stock worth $36,648,000 after buying an additional 460,473 shares during the last quarter. TD Asset Management Inc lifted its position in shares of Amphastar Pharmaceuticals by 449.0% during the 4th quarter. TD Asset Management Inc now owns 793,559 shares of the company’s stock worth $49,082,000 after buying an additional 649,001 shares during the last quarter. Victory Capital Management Inc. lifted its position in shares of Amphastar Pharmaceuticals by 870.9% during the 4th quarter. Victory Capital Management Inc. now owns 237,474 shares of the company’s stock worth $14,688,000 after buying an additional 213,014 shares during the last quarter. Finally, Shaker Investments LLC OH lifted its position in shares of Amphastar Pharmaceuticals by 136.0% during the 4th quarter. Shaker Investments LLC OH now owns 49,078 shares of the company’s stock worth $3,035,000 after buying an additional 28,283 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.